CSBio CSBio

X
[{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bio-Thera Solutions"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"$20.0 million","newsHeadline":"Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bio-Thera Solutions"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Pharmapark","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara\u00ae Biosimil","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bio-Thera Solutions"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Provides Business and Clinical Development Program Update","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Connect Biopharma"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Biomm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara\u00ae Biosimilar","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Bio-Thera Solutions"},{"orgOrder":0,"company":"Minghui Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Minghui Pharmaceutical"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akeso Announced NDA Acceptance of IL-12\/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Akeso"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","amount":"$141.0 million","upfrontCash":"$21.0 million","newsHeadline":"Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Connect Biopharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.

            Lead Product(s): Rademikibart

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Jiangsu Simcere Pharmaceutical

            Deal Size: $141.0 million Upfront Cash: $21.0 million

            Deal Type: Licensing Agreement November 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            AK101 (ebdarokimab) is a novel fully human Interleukin-12/Interleukin-23 monoclonal antibody, which is investigated for the treatment of adult patients with moderate-to-severe plaque-type psoriasis.

            Lead Product(s): Ebdarokimab

            Therapeutic Area: Dermatology Product Name: AK101

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MH004 is the investigational topical cream,currently in phase 3 clinical study for targeting mild to moderate atopic dermatitis. The topline data of the phase 3 trial with the medical community and regulatory authorities in H2 2024.

            Lead Product(s): MH004

            Therapeutic Area: Dermatology Product Name: MH004

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Biomm will have exclusive rights to distribute and market BAT2206 (ustekinumab), a proposed biosimilar to Janssen’s Stelara, in Brazil for the treatment of active psoriatic arthritis.

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: BAT2206

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biomm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.

            Lead Product(s): Pyrilutamide

            Therapeutic Area: Dermatology Product Name: KX-826

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IBI112 (picankibart) specifically binds to IL-23p19 inhibiting IL-23 receptor-mediated signaling pathway. Preclinical data demonstrated that picankibart has a clear target and well-elucidated mechanism of action and significant anti-inflammatory effect.

            Lead Product(s): Picankibart,IBI311

            Therapeutic Area: Dermatology Product Name: IBI311

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. As an inhibitor of IL-4Rα, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13.

            Lead Product(s): CBP-201

            Therapeutic Area: Dermatology Product Name: CBP-201

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This partnership will leverage Pharmapark’s strong local presence, sales and marketing capabilities in Russia and other CIS countries. Bio-Thera will be responsible for full development, and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou, China.

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: BAT2206

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pharmapark

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206. Hikma will have exclusive rights to commercialize the product in the US.

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: BAT2206

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: $150.0 million Upfront Cash: $20.0 million

            Deal Type: Licensing Agreement August 27, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The clinical study is a multicenter, randomized, double-blind, and parallel controlled study to compare the efficacy and safety of BAT2206 to Stelara® in moderately to severely psoriatic (PsO) patients that is expected to enroll approximately 472 volunteers.

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: BAT2206

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY